Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in h

[News]

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

More... (https://www.news-medical.net/news/20241214/Adjuvant-anthracycline-plus-taxane-based-chemotherapy-regimen-improves-survival-in-high-risk-breast-cancer-patients.aspx)